<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99302">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01811875</url>
  </required_header>
  <id_info>
    <org_study_id>8VWF07</org_study_id>
    <nct_id>NCT01811875</nct_id>
  </id_info>
  <brief_title>Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A</brief_title>
  <official_title>Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bio Products Laboratory</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bio Products Laboratory</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: To assess post-marketing immunogenicity of Optivate® by monitoring plasma
      inhibitor levels for at least 100 Exposure Days (EDs) for each subject.

      Secondary objectives: To assess efficacy and tolerability by monitoring FVIII recovery and
      adverse events
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess post-marketing immunogenicity of Optivate by monitoring plasma inhibitor levels for at least 100 Exposure Days for each subject.</measure>
    <time_frame>At least 100 Exposure Days for each subject. Subjects will attend 5 visits over a period of up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess efficacy and tolerability</measure>
    <time_frame>Over a period of 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Haemophilia A</condition>
  <arm_group>
    <arm_group_label>Optivate 500IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optivate 500IU</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Optivate 500IU</intervention_name>
    <arm_group_label>Optivate 500IU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent or, if less than 18 years of age written assent (where
             possible) and their parent/guardian's written informed consent.

          -  Severe haemophilia A (&lt; 1%# FVIII:C).

          -  Previously Treated Patients (PTPs) with &gt; 150 exposure days on prior Factor VIII
             therapy (of which at least the last 50 EDs or 2 years treatment can be confirmed by
             way of subject records).

          -  Immunocompetent with CD4 count &gt; 200 / µl.

          -  HIV negative or a viral load &lt; 200 particles / µl.

               -  subjects suffering from severe haemophilia A (&lt;2%) may be enrolled, but only
                  after approval by BPL. Subjects with a Factor VIII of &lt;2% may not constitute
                  more than 50% of the total patient population. A separate statistical evaluation
                  will be conducted for the &lt;1% and &lt;2% populations.

        Exclusion Criteria:

          -  • History of inhibitor development to FVIII or a positive result on the Nijmegen
             Bethesda at screening (quantitative result of &gt; 0.6 BU) prior to the administration
             of Optivate®.

               -  Known or suspected hypersensitivity to the investigational medicinal product or
                  its excipients.

               -  Clinically significant liver disease, renal disease, or coagulopathy other than
                  haemophilia A.

               -  History of unreliability or non cooperation (including not being able to
                  complete the study diary).

               -  Participating in, or have taken part in another trial within the last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Wolford</last_name>
    <role>Study Director</role>
    <affiliation>Bio Products Laboratory</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Head of Medical Affairs</last_name>
    <phone>+44(0) 208 957 2200</phone>
    <email>medinfo@bpl.co.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Wilson</last_name>
    <phone>+44(0) 208 957 2240</phone>
    <email>lisa.wilson@bpl.co.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fundacion BIOS</name>
      <address>
        <city>Barranquilla</city>
        <zip>80-216</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital general de Medellin</name>
      <address>
        <city>Medellin</city>
        <zip>32-102</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>HZRM Haemophilia Centre Rhine Main</name>
      <address>
        <city>Moerfelden-Walldorf</city>
        <state>Hessen</state>
        <zip>64546</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. M. Kopernika</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek Trelinski, Dr</last_name>
      <phone>+48 12 623 07 15</phone>
      <email>sskrzynska@brillance.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Thomas' Hospital, Centre for Haemostasis and Thrombosis</name>
      <address>
        <city>Long Ashton</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Austin, Dr</last_name>
      <phone>020 7188 7188</phone>
      <phone_ext>52464</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 16, 2016</lastchanged_date>
  <firstreceived_date>March 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemophilia A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
